Sanofi Aventis Us Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for SANOFI AVENTIS US, and when can generic versions of SANOFI AVENTIS US drugs launch?
SANOFI AVENTIS US has one hundred and twenty-two approved drugs.
There are eleven US patents protecting SANOFI AVENTIS US drugs.
There are two hundred and fifty-seven patent family members on SANOFI AVENTIS US drugs in fifty-three countries and one hundred and ten supplementary protection certificates in nineteen countries.
Summary for Sanofi Aventis Us
International Patents: | 257 |
US Patents: | 11 |
Tradenames: | 97 |
Ingredients: | 85 |
NDAs: | 122 |
Drugs and US Patents for Sanofi Aventis Us
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | CHRONULAC | lactulose | SOLUTION;ORAL | 017884-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | |||||
Sanofi Aventis Us | SLO-PHYLLIN | theophylline | CAPSULE, EXTENDED RELEASE;ORAL | 085205-001 | May 24, 1982 | DISCN | No | No | See Plans and Pricing | See Plans and Pricing | |||||
Sanofi Aventis Us | SLO-PHYLLIN | theophylline | TABLET;ORAL | 085202-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | See Plans and Pricing | See Plans and Pricing | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Sanofi Aventis Us
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sanofi Aventis Us | ARAVA | leflunomide | TABLET;ORAL | 020905-003 | Sep 10, 1998 | 4,284,786 | See Plans and Pricing |
Sanofi Aventis Us | LOVENOX (PRESERVATIVE FREE) | enoxaparin sodium | INJECTABLE;SUBCUTANEOUS | 020164-004 | Mar 27, 1998 | 5,389,618 | See Plans and Pricing |
Sanofi Aventis Us | JEVTANA KIT | cabazitaxel | SOLUTION;INTRAVENOUS | 201023-001 | Jun 17, 2010 | 5,438,072 | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for SANOFI AVENTIS US drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 7 mg and 14 mg | ➤ Subscribe | 2016-09-12 |
➤ Subscribe | Tablets | 300 mg/25 mg | ➤ Subscribe | 2006-06-06 |
➤ Subscribe | Tablets | 400 mg | ➤ Subscribe | 2013-07-01 |
➤ Subscribe | Injection | 5 mg/mL, 10 mL and 20 mL vials | ➤ Subscribe | 2007-02-09 |
➤ Subscribe | Injection | 200 mg/40 mL | ➤ Subscribe | 2007-07-16 |
➤ Subscribe | Injection | 100 mg/mL, 3 mL vials | ➤ Subscribe | 2006-12-07 |
➤ Subscribe | Extended-release Tablets | 12.5 mg | ➤ Subscribe | 2006-01-19 |
➤ Subscribe | Tablets | 150 mg/12.5 mg and 300 mg/12.5 mg | ➤ Subscribe | 2004-11-10 |
➤ Subscribe | Tablets | 75 mg, 150 mg and 300 mg | ➤ Subscribe | 2004-05-25 |
➤ Subscribe | Tablets | 300 mg | ➤ Subscribe | 2009-03-04 |
➤ Subscribe | Injection | 40 mg/mL, 0.5 mL and 2 mL vials | ➤ Subscribe | 2009-06-30 |
➤ Subscribe | For Injection | 50 mg/vial and 100 mg/vial | ➤ Subscribe | 2007-02-09 |
➤ Subscribe | Injection | 5 mg/mL, 40 mL vial | ➤ Subscribe | 2011-03-23 |
➤ Subscribe | Extended-release Tablets | 6.25 mg | ➤ Subscribe | 2006-02-24 |
Premature patent expirations for SANOFI AVENTIS US
Expiration due to failure to pay maintenance fee
Patent Number | Expiration Date |
---|---|
See Plans and Pricing | See Plans and Pricing |
International Patents for Sanofi Aventis Us Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Nicaragua | 201000173 | See Plans and Pricing |
China | 104784187 | See Plans and Pricing |
Croatia | P20130322 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Sanofi Aventis Us Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2768484 | 132019000000144 | Italy | See Plans and Pricing | PRODUCT NAME: DAUNORUBICINA E CITARABINA(VYXEOS); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1308, 20180827 |
1110543 | 08C0004 | France | See Plans and Pricing | PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730 |
0100718 | 96C0006 | Belgium | See Plans and Pricing | PRODUCT NAME: TILUDRONATE DISODIQUE EXPRIME EN ACIDE TILUDRONIQUE; NAT. REGISTRATION NO/DATE: 201 IS 106 F 3 19950907; FIRST REGISTRATION: LI 53014 19950220 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.